Latest Astellas Pharma Inc. Stories
On-course Women's Pavilion also at tournament as part of the PGA TOUR's Women's Initiative, sponsored by Astellas FORT WORTH, Texas and NORTHBROOK, Ill., May 21, 2013 /PRNewswire/ -- The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today will feature CBS sportscaster Lesley Visser at the Astellas Presents Executive Women's Day, a day-long forum focusing on professional, health-related and personal development...
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that results of three studies of MYRBETRIQ(®) (mirabegron) as a treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency were presented in poster sessions at the American Urological Association Annual (AUA) Meeting in San Diego. The first two studies demonstrated the...
NORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana, have collaborated to raise awareness of the need for more organ donors in the city of Chicago. As part of the...
NORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana, have collaborated to raise awareness of the need for more organ donors in the state of Illinois. As part of the...
CHERTSEY, England, April 19, 2013 /PRNewswire/ -- Clostridiumdifficile infection (CDI), a potentially fatal disease, is one of the most common healthcare-associated infections[1] Urgent action is needed to improve the diagnosis and management of CDI, which is the main cause of hospital-acquired (nosocomial) diarrhoea in industrialised countries.[2] In a report launched today, during a meeting hosted by the European Healthcare and Hospital Federation (HOPE), experts...
Findings are encouraging, however, as majority of respondents are generally knowledgeable about organ donation NORTHBROOK, Ill., April 15, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced results of a national survey which found that while 60 percent of respondents were familiar with their state organ donor registries and 57 percent would be willing to have their organs donated after they...
TOKYO, April 14, 2013 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas' Headquarters for the Americas in Northbrook, Illinois, USA and will report to Sef Kurstjens, M.D., Ph.D., newly named Chief Medical Officer at Astellas. In April 2013, Astellas established the Chief Medical Officer position in order to further integrate and enhance...
Myrbetriq is now available in pharmacies across Canada MARKHAM, ON, April 10, 2013 /CNW/ - Overactive bladder (OAB) is a chronic, debilitating condition that can have a profound, negative impact on a patient's quality of life.( 1) Many patients with OAB are plagued by depression,(2) experience a disruption in sleep,(3) limit their social activity,(4) and experience a loss of control and decreased self-esteem.(5) An estimated 2.9 million Canadian men and women(6) suffer from OAB...
TOKYO and SAN DIEGO, April 4, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, "Astellas") today entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high...
CHICAGO, March 28, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bayer (OTC:BAYRY), Johnson & Johnson (NYSE:JNJ), Novo Nordisk (NYSE:NVO), AbbVie Inc. (NYSE:ABBV) and Astellas Pharma, Inc. (OTC:ALPMY). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...
